ClinicalTrials.gg

Program

CS32582

A development code. Also written as “CS32582 capsule(low dose)”, “CS32582 capsule(medium dose)” and “CS32582 capsule(high dose)”.

Its studies are mostly in Psoriasis, led by Chipscreen Biosciences.

Furthest: phase 2, since Aug 11, 20252 company-led studies, 1 open or runningNext primary completion: Sep 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciences21 open or runningphase 2since Aug 11, 2025Jan 16, 2024Sep 18, 2027phase 2 · NCT07129382

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 16, 2024First study: phase 1 study in HealthyFirst studyNCT06224595 · 112 enrolled · China
  2. Aug 11, 2025Phase 2 study in Plaque PsoriasisNCT07129382 · 220 planned · China

Ahead

  1. Sep 18, 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07129382

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07129382Plaque Psoriasis · China2RecruitingSep 18, 2027220
NCT06224595Healthy · China1CompletedNov 27, 2024112

How it is read

Names in the registry

  • “CS32582 capsule(low dose)”, 1 entry
  • “CS32582 capsule(medium dose)”, 1 entry
  • “CS32582 capsule(high dose)”, 1 entry
  • “CS32582 capsule”, 1 entry

Codes read as this program: CS32582.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.